<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Repository of the Max Delbrück Center for Molecular Medicine (MDC) in the Helmholtz Association</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2015">2015 MAY 22</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><roleName>M.D</roleName><forename type="first">Tanja</forename><surname>Schneider</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Hematology, Oncology and Tumor Immunology</orgName>
								<orgName type="institution">Charité University Medicine</orgName>
								<address>
									<addrLine>Campus Virchow-Klinikum</addrLine>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="institution">and Labor Berlin Charité Vivantes GmbH</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">A</forename><surname>Floercken</surname></persName>
						</author>
						<author>
							<persName><roleName>M.D</roleName><forename type="first">Anju</forename><surname>Singh</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Hematology, Oncology and Tumor Immunology</orgName>
								<orgName type="institution">Charité University Medicine</orgName>
								<address>
									<addrLine>Campus Virchow-Klinikum</addrLine>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="institution">and Labor Berlin Charité Vivantes GmbH</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">S</forename><surname>Tuerkmen</surname></persName>
						</author>
						<author>
							<persName><forename type="first">T</forename><surname>And Burmeister</surname></persName>
						</author>
						<author>
							<persName><roleName>M.D</roleName><forename type="first">Ioannis</forename><surname>Anagnostopoulos</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">Institute of Pathology</orgName>
								<orgName type="institution">Charité University Medicine</orgName>
								<address>
									<addrLine>Campus Mitte</addrLine>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>M.D</roleName><forename type="first">Antonio</forename><surname>Pezzutto</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Department of Hematology, Oncology and Tumor Immunology</orgName>
								<orgName type="institution">Charité University Medicine</orgName>
								<address>
									<addrLine>Campus Benjamin Franklin</addrLine>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">B</forename><surname>Doerken</surname></persName>
						</author>
						<author role="corresp">
							<persName><roleName>M.D</roleName><forename type="first">Anne</forename><surname>Flörcken</surname></persName>
							<email>anne.floercken@charite.de</email>
							<affiliation key="aff0">
								<orgName type="department">Department of Hematology, Oncology and Tumor Immunology</orgName>
								<orgName type="institution">Charité University Medicine</orgName>
								<address>
									<addrLine>Campus Virchow-Klinikum</addrLine>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="institution">and Labor Berlin Charité Vivantes GmbH</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>M.D</roleName><forename type="first">Seval</forename><surname>Türkmen</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Institute of Medical Genetics and Human Genetics</orgName>
								<orgName type="institution">Charité University Medicine</orgName>
								<address>
									<addrLine>Campus Virchow-Klinikum</addrLine>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="institution">and Labor Berlin Charité Vivantes GmbH</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>M.D</roleName><forename type="first">Thomas</forename><surname>Burmeister</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Department of Hematology, Oncology and Tumor Immunology</orgName>
								<orgName type="institution">Charité University Medicine</orgName>
								<address>
									<addrLine>Campus Benjamin Franklin</addrLine>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>M.D</roleName><forename type="first">Bernd</forename><surname>Dörken</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Hematology, Oncology and Tumor Immunology</orgName>
								<orgName type="institution">Charité University Medicine</orgName>
								<address>
									<addrLine>Campus Virchow-Klinikum</addrLine>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="institution">and Labor Berlin Charité Vivantes GmbH</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>M.D</roleName><forename type="first">Jörg</forename><surname>Westermann</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Hematology, Oncology and Tumor Immunology</orgName>
								<orgName type="institution">Charité University Medicine</orgName>
								<address>
									<addrLine>Campus Virchow-Klinikum</addrLine>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="institution">and Labor Berlin Charité Vivantes GmbH</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff6">
								<orgName type="department">Department of Hematology, Oncology and Tumor Immunology</orgName>
								<orgName type="institution">Charité University Medicine</orgName>
								<address>
									<addrLine>Campus Virchow-Klinikum</addrLine>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff7">
								<orgName type="institution">and Labor Berlin Charité Vivantes GmbH</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Repository of the Max Delbrück Center for Molecular Medicine (MDC) in the Helmholtz Association</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2015">2015 MAY 22</date>
						</imprint>
					</monogr>
					<idno type="MD5">0C2BBAFF75E694C8A9C675FD49D3313E</idno>
					<idno type="DOI">10.1007/s00277-015-2400-5</idno>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:30+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>AML</term>
					<term>flow cytometry</term>
					<term>maturity</term>
					<term>prognosis</term>
					<term>score</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>The European LeukemiaNet (ELN) classification is widely accepted for risk stratification of patients with acute myeloid leukemia (AML).</s><s>In order to establish immunophenotypic features that predict prognosis, the expression of single AML blast cell antigens has been evaluated with partly conflicting results; however, the influence of immunophenotypic blast maturity is largely unknown.</s></p><p><s>In our study, 300 AML patients diagnosed at our institution between 01/2003 and 04/2012 were analyzed.</s><s>A flow cytometric maturity score was developed in order to distinguish "mature" AML (AML-ma) from "immature" AML (AML-im) by quantitative expression levels of early progenitor cell antigens (CD34, CD117, and TdT).</s></p><p><s>AML-ma showed significantly longer relapse-free survival (RFS) and overall survival (OS) than AML-im (p&lt;0.001).</s><s>Interestingly, statistically significant differences in RFS and OS were maintained within the "intermediate risk" group according to ELN (RFS: 7.0 years (AML-ma) vs. 3.3 years (AML-im); p=0.002;</s><s>OS: 5.1 years (AML-ma) vs. 3.0 years (AML-im); p=0.022).</s></p><p><s>Our novel flow cytometric score easily determines AML blast maturity and can predict clinical outcome.</s><s>It remains to be clarified whether these results simply reflect an accumulation of favorable molecular phenotypes in the AML-ma subgroup or whether they rely on biological differences such as a higher proportion of leukemia stem cells and/or a higher degree of genetic instability within the AML-im subgroup.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p><s>Acute myeloid leukemia (AML) is a malignant haematopoietic neoplasm mainly occurring in elderly patients ≥65 years of age <ref type="bibr" target="#b0">[1]</ref>.</s><s>Cytogenetic and molecular genetic abnormalities are thought to drive clonal expansion of early haematopoietic progenitor cells, which leads to rapid progressive suppression of normal bone marrow haematopoiesis.</s><s>Subsequently, patients suffering from AML develop symptoms attributed to granulocytopenia, anaemia, and thrombocytopenia <ref type="bibr" target="#b1">[2]</ref>.</s><s>Besides age, cytogenetic and molecular features are the main prognostic factors that influence survival <ref type="bibr" target="#b2">[3,</ref><ref type="bibr" target="#b3">4]</ref>.</s><s>Hence, in 2009 the European LeukemiaNet (ELN) proposed a standardized reporting system that risk stratifies patients according to their genetic subgroup.</s><s>As of today, it is well established for early prognostic assessment in AML patients <ref type="bibr" target="#b4">[5,</ref><ref type="bibr" target="#b3">4,</ref><ref type="bibr" target="#b6">6,</ref><ref type="bibr" target="#b7">7,</ref><ref type="bibr" target="#b2">3,</ref><ref type="bibr" target="#b8">[8]</ref><ref type="bibr" target="#b9">[9]</ref><ref type="bibr" target="#b10">[10]</ref>.</s><s>Thus, patients in this cohort were primarily grouped according to these criteria <ref type="bibr" target="#b4">[5]</ref>.</s></p><p><s>In addition to conventional cytogenetics and molecular genetics, flow cytometric analysis of blast cells plays an essential role in diagnosing AML.</s><s>The prognostic significance of the expression of particular antigens remains controversial with previous studies mostly focusing on single antigens <ref type="bibr" target="#b11">[11]</ref><ref type="bibr" target="#b12">[12]</ref><ref type="bibr" target="#b13">[13]</ref><ref type="bibr" target="#b15">[14]</ref>.</s><s>In contrast, the influence of 3 immunophenotypic maturity of AML blasts on overall prognosis is largely unknown.</s><s>This is the first study using a quantitative score, consisting of three routinely used early progenitor cell markers for the assessment of AML blast maturity.</s><s>The study was conducted to determine the influence of blast maturity on clinical parameters such as complete/incomplete remission after induction (CR/CRi), relapse-free survival (RFS), and overall survival (OS) both in the whole cohort and within the different risk groups according to ELN.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Patients and Methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Patients</head><p><s>Patients included in this study were ≥18 years and newly diagnosed with AML at the Charité University Medical Center Berlin, Campus Virchow Klinikum, from 01/2003 through 04/2012.</s><s>Only patients with available flow cytometry report from our institution were included.</s><s>AML-related data and patient demographics were collected for each patient.</s><s>These included morphologic findings, conventional cytogenetics, molecular genetics (FLT3, NPM1, and MLL), blood count, type of treatment, date of CR/CRi as well as date of relapse, stem cell transplantation and death (Table <ref type="table" target="#tab_0">1</ref>).The retrospective study was performed after informed consent for bone marrow diagnostics and was in accordance with the local ethical guidelines.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Flow cytometric analysis</head><p><s>Of the 300 patients eligible for this study, flow cytometric analysis of bone marrow (n=284) or peripheral blood (n=16) was performed.</s><s>EDTA samples were obtained and subsequently incubated with fluorochrome-labeled antibodies (FITC, PE, PC5.5, or APC) for the detection of cell surface antigens (CD1a, CD2, CD3, CD4, CD5, CD7, CD7.1/NG2, CD8, CD10, CD11b, CD11c, CD13, CD14, CD15, CD19, CD20, CD22, CD33, CD34, CD36, CD38, CD56, CD64, CD65, CD117, CD133, CD235a, HLA-DR) and intracytoplasmatic antigens (MPO, TdT, LF, cyCD3, cyCD22, cyCD79a) using BD FACSCalibur or BD FACSCanto TM systems (Becton, Dickinson and Company, San Jose, CA, USA).</s><s>BD FACSDiva TM or BD CellQuest TM software was used for analysis of flow cytometry data.</s><s>The blast cell population was identified by CD45/side scatter (SSC) gating of at least 30,000 cells.</s><s>Antigen expression was considered positive when ≥20% (surface antigens) or ≥10% (intracellular antigens) gated cells were positive.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>AML maturity score</head><p><s>To classify AML according to the degree of maturity, a score based on the quantitative expression of CD34, CD117 and TdT was developed.</s><s>All three markers are clearly associated with immaturity, can easily be 4 quantified, and had been evaluated over the whole study period <ref type="bibr" target="#b17">[15]</ref>.</s><s>The maturity score was weighed towards CD34 and TdT, since these markers show a particularly strong correlation with immaturity.</s><s>As shown in Table <ref type="table">2a</ref>, a score of 5 indicates maximal immaturity and a score of 0 indicates maturity.</s><s>Table <ref type="table">2b</ref> shows the distribution of patients within the different "maturity groups".</s><s>A cut-off value of &lt;1.5 points was the strongest discriminator with regard to RFS and OS (p&lt;0.001,</s><s>respectively) as determined by Kaplan-Meier survival curves.</s><s>The cut-off value was not determined by the standardized median-split method, as the cut-off value of &lt;1.5 points was a stronger discriminator with regard to RFS and OS.</s><s>The purpose of this classification was to achieve a factor variable with two groups that can be used to describe the influence of the immaturity on the RFS and OS within a Kaplan-Meier-Analysis based on the developed score.</s></p><p><s>Consequently, 109 patients (39.5%) were assigned to the "mature" group (0-1 points; "AML-ma") and 167 patients (60.5%) to the "immature" group (1.5-5 points, "AML-im").</s><s>The maturity score showed a good correlation with morphological maturity according to the FAB classification (data not shown).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Data collection was performed using IBM SPSS Statistics®, version 20 (IBM® 2011, Armonk, NY, USA).</head><p><s>Clinical parameters were CR/CRi, defined as bone marrow blasts &lt;5% with or without blood count recovery after induction therapy, RFS and OS <ref type="bibr" target="#b4">[5]</ref>.</s><s>Survival characteristics were analyzed by means of the Kaplan Meier method.</s><s>Differences were determined by the Chi Square and Fisher's Exact Test (CR/CRi) and the Log rank test (RFS, OS).</s><s>A p-value of p&lt;0.05 was considered significant.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Patients' characteristics</head><p><s>The baseline characteristics of the patients are given in Table <ref type="table" target="#tab_0">1</ref>.</s><s>Median age at diagnosis was 61 years with a male predominance.</s><s>Cytogenetic abnormalities were detected in n=170/273 patients (62.3%).</s><s>Molecular genetic alterations (NPM1, FLT3, MLL) were found in n=92/256 patients (35.9%).</s><s>Patients with incomplete cytogenetic results or mixed phenotype leukemias (n=53) were excluded from the analysis within the different ELN risk groups.</s><s>Hence, we were able to assign 247/300 patients to an ELN risk group.</s><s>The mean follow-up of all patients was 29.4 months (range 0-116.5 months).</s><s>206 of 300 (69%) patients reached CR/CRi after induction chemotherapy.</s><s>In patients &lt;60 years of age (n=141/300), the CR/CRi rate was 81.6% vs. 57.2% in patients ≥60 years (n=159/300), (p&lt;0.001).</s><s>Mean RFS was 69.5 months with a higher RFS in patients &lt;60 years (76.9 months vs. 58.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5">Immunophenotypic maturity and clinical outcome</head><p><s>In 276 of 300 patients (92%) the maturity score could be determined.</s><s>In 24 of 300 patients, flow cytometric analysis did not include all necessary parameters for the calculation of the novel maturity score.</s><s>Regarding the CR/CRi rate, a tendency towards higher CR/CRi rates was observed in AML-ma (AML-ma: 73.4% vs. AML-im: 64.1%, p=0.115), however, this was not statistically significant, neither in the group as a whole nor in subgroups divided by age, &lt;60 years vs. ≥60 years (data not shown).</s></p><p><s>In contrast, AML-ma showed a significantly longer mean RFS (89.4 months) when compared to AML-im (51.5 months), (p&lt;0.001).</s><s>This difference was consistently found both in the whole cohort and in the age-related subgroups: In patients &lt;60 years, the mean RFS was 92.1 months for AML-ma patients and 58.4 months for AML-im patients) (p=0.005)</s><s>(Fig <ref type="figure">2a</ref>).</s><s>In patients ≥60 years, RFS was 82.7 months for patients with AML-ma vs.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="42.2">months for AML-im patients (p=0.01) (Fig 2b).</head><p><s>Regarding OS, patients in the AML-ma group had a longer mean OS (63.8 months) than patients in the AML-im group (32.9 months) (p&lt;0.001).</s><s>Again, this difference was consistently observed both in the whole cohort and in age-related subgroups (AML patients &lt;60 years: p&lt;0.001 and AML patients ≥60 years: p=0.033) (Fig <ref type="figure">2c,d</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Influence of immunophenotypic maturity on clinical parameters within the different ELN risk groups</head><p><s>In order to further evaluate our immunophenotypic maturity score, the patients were categorized according to the ELN risk groups.</s><s>The subdivision of the intermediate ELN risk group into "intermediate 1" and "intermediate 2" has so far been controversial.</s><s>Therefore, we combined these two groups into one intermediate risk group.</s><s>Thus, adequate patient numbers within the three different groups were obtained.</s><s>In our AML cohort, the following risk groups according to ELN were determined: favorable risk (n=45), intermediate risk (n=132), and adverse risk (n=70).</s><s>Within these different risk groups according to ELN, clinical parameters such as CR/CRi rate, RFS, and OS were consistent with the published literature <ref type="bibr" target="#b4">[5]</ref>.</s><s>In the ELN subgroups "favorable" vs. "intermediate" vs.</s></p><p><s>"adverse" CR/CRi rates were 86.7% vs. 78.0%</s><s>vs. 55.7% (p&lt;0.001),</s><s>RFS was 93.8 months vs. 62.5 months vs.</s></p><p><s>53.1 months (p=0.002) and OS was 77.5 months vs. 49.7 months vs. 28.0</s><s>months (p&lt;0.001)</s><s>(data not shown).</s></p><p><s>Subsequently, the influence of our novel maturity score was evaluated within the ELN subgroups with regard to clinical parameters such as CR/CRi rate, RFS, and OS.</s><s>Within the defined ELN risk groups, AML-ma showed higher CR/CRi rates than the AML-im patients.</s></p><p><s>However, these differences did not reach statistical significance (data not shown).</s><s>Regarding survival, in the 6 "favorable risk" group a longer RFS was observed in patients with AML-ma as compared to AML-im (102.5 months vs. 83.7 months), however, this difference was not statistically significant (p=0.214)</s><s>(Fig <ref type="figure">4a</ref>).</s><s>In contrast, in the "intermediate risk" group, which was the largest in our cohort, a highly significant difference in RFS in favor of the AML-ma subgroup was observed (84.5 months vs. 39.7 months, p=0.002) (Fig <ref type="figure">4c</ref>).</s><s>In the "adverse risk" group, no difference could be observed (data not shown).</s></p><p><s>Furthermore, a longer OS in AML-ma patients as compared to AML-im patients could be observed across all ELN risk groups.</s><s>However, this difference in OS reached statistical significance only in the "intermediate" risk group (AML-ma 61.4 months vs. 35.6</s><s>months, p=0.022) (Fig <ref type="figure">4b</ref>).</s></p><p><s>In order to exclude that these differences were caused by an imbalance of patients who had undergone allogeneic bone marrow transplantation (n=77/276), the analyses were repeated for all patients who had not been transplanted (n=223/276).</s><s>Nevertheless, the differences in RFS and OS were maintained after exclusion of patients who had undergone allogeneic stem cell transplantation.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Biological phenotype in maturity groups and ELN subgroups</head><p><s>In order to further characterize the subgroup of AML patients who were categorized as AML-ma and AML-im according to our maturity score, we analyzed the frequency of cytogenetic and molecular aberrations in both subgroups.</s><s>In the AML-ma subgroup we found a significant accumulation of PML-RARA and NPM1 mut (ELN subgroup "favorable risk") and CN-AML (ELN subgroup "intermediate risk").</s><s>In contrast, in the AML-im subgroup, there was a substantial accumulation of adverse phenotypes such as complex aberrant and monosomal karyotypes (ELN subgroup "adverse risk").</s><s>The differences are shown in Table <ref type="table">3</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>To the best of our knowledge, this is the first study evaluating AML blast maturity by means of a quantitative flow cytometric score in order to predict clinical outcome.</s><s>We were able to show that a mature AML blast immunophenotype (AML-ma) was associated with a significantly longer RFS and OS than an immature immunophenotype (AML-im), (p&lt;0.001).</s><s>This was at least partly attributable to an accumulation of "low-risk" AML phenotypes such as NPM1 mut and PML-RARA in the AML-ma group.</s><s>"High-risk" aberrations (monosomal and complex aberrant karyotypes, -5 or del(5q), -7) had a higher frequency in the immature subgroup (see Table <ref type="table">3</ref>).</s></p><p><s>However, the differences in RFS and OS were maintained in a subgroup analysis within the different ELN risk groups.</s><s>Statistical significance was only obtained in the "intermediate risk" group according to ELN with AML-ma being superior to AML-im with regard to RFS (p=0.002) and OS (p=0.022).</s><s>No statistical significance could be observed in the favorable and adverse risk groups, possibly due to lower patient numbers in these subgroups.</s></p><p><s>Although there was a trend towards better CR/CRi rates within the AML-ma subgroup, these differences were not statistically significant.</s></p><p><s>The median age at first diagnosis of AML was 61 years in our patient cohort and is somewhat lower than reported in the literature (median about 67 years) <ref type="bibr" target="#b0">[1]</ref>.</s><s>This might explain, why our 5-year overall survival rate of 38.3% is higher than in previously published reports such as the US cancer registry (24.9%) <ref type="bibr" target="#b0">[1]</ref>.</s><s>A Swedish registry study showed a decrease in 5-year overall survival with every 5-years of age increase (&lt;50 years: 51%, 50-54 years: 40%, 55-59 years: 23%, 60-64 years: 23%, 65-69 years: 13%, 70-74 years: 5%, 75-79 years: 3%, 80-84 years: 2%, ≥85 years: 0%) <ref type="bibr" target="#b18">[16]</ref>.</s></p><p><s>Additionally, our study included only patients with a comprehensive flow cytometric report, thereby indirectly excluding patients not suitable for intensive treatment since in those patients initial diagnostics are often restricted to morphologic evaluation.</s><s>The monocentric design of the study at a large university center further enhances a selection bias towards younger patients in good clinical condition.</s></p><p><s>The assignment to the different ELN risk groups was determined by cytogenetic and molecular data.</s><s>During the study period, routine molecular genetic analyses performed in AML patients at initial diagnosis have become more and more comprehensive, whereas these analyses were performed with lower frequency and contained less molecular markers at the beginning of the study period.</s><s>This may explain the lower frequency of molecular aberrations observed in our study as compared with the literature.</s><s>Furthermore, many molecular aberrations which may impact clinical outcome (such as c-kit, DNMT3A and IDH mutations) have not been analyzed andmore importantly -are not yet integrated in the ELN risk stratification.</s><s>It is very likely that the possible underestimation of molecular phenotypes in the current ELN risk classification in combination with a lack of data concerning particular molecular phenotypes has affected the risk classification within our study, particularly within the CN-AML group.</s><s>However, this is an inherent limitation of AML risk stratification at a certain point in time and it certainly does not diminish our main conclusion that AML blast maturity does impact clinical outcome, irrespective of the underlying causes.</s></p><p><s>However, having said this, there is no reason to assume a systematic bias towards a better or an inferior survival which has influenced our main conclusion concerning AML maturity.</s></p><p><s>For the first time, our study shows a combined quantitative analysis of early progenitor markers in AML.</s><s>The particular marker combination was chosen because it is 1) widely used, 2) allows for an easy quantification of the marker expression on AML blasts and 3) was continuously used throughout the study period.</s><s>Although TdT might be considered an unusual marker for AML, its correlation with blast immaturity is particularly strong <ref type="bibr" target="#b20">[17]</ref>.</s></p><p><s>We found that blast immaturity is correlated with particular phenotypes such as complex aberrations, monosomal karyotypes, accrual of chromosome 13 and a loss of chromosomes 5, 5q, and 7.</s><s>In contrast, PML-RARA and NPM1 mutations had a higher frequency in the in the AML-ma group.</s><s>These results are supported by previous studies, in which AML FAB M0 was associated an accumulation the same adverse chromosomal aberrations, a higher age and consequently a worse outcome <ref type="bibr" target="#b21">[18]</ref><ref type="bibr" target="#b22">[19]</ref><ref type="bibr" target="#b23">[20]</ref>.</s><s>Furthermore, also in recently published studies, a lower frequency of favorable molecular aberrations such as NPM1 and CEBPA has been described in the more immature AML subgroup AML FAB M0 <ref type="bibr" target="#b25">[21]</ref>.</s><s>Finally, the expression of CD34 in NPM1-and FLT3-ITDmutated AML seems to be associated with a worse clinical outcome <ref type="bibr" target="#b26">[22,</ref><ref type="bibr" target="#b28">23]</ref> and it was recently reported that CD34 expression has negative impact in patients with acute promyelocitic leukemia <ref type="bibr" target="#b29">[24]</ref>.</s></p><p><s>Apparently, all these results give rise to the question whether AML maturity is only a surrogate parameter for more favorable phenotypes or whether there is possibly also a causative biological relationship between maturity and a more favorable outcome.</s></p><p><s>Within a category of more biological explanations, a higher genetic instability due to higher proliferation rates in immature cells might account for a higher probability of further genetic aberrations causing "clonal evolution" towards a more aggressive genotype with increasing resistance to therapy <ref type="bibr" target="#b31">[25]</ref><ref type="bibr" target="#b32">[26]</ref><ref type="bibr" target="#b33">[27]</ref>.</s></p><p><s>Another hypothetical biological explanation is related to an increasing frequency of leukemic stem cells (LSC) within immature AML.</s><s>Since these LSC -particularly in their dormant stage -may survive treatment and give rise to subsequent relapse <ref type="bibr" target="#b22">[19,</ref><ref type="bibr" target="#b37">[28]</ref><ref type="bibr" target="#b38">[29]</ref><ref type="bibr" target="#b39">[30]</ref><ref type="bibr" target="#b40">[31]</ref><ref type="bibr" target="#b41">[32]</ref><ref type="bibr" target="#b42">[33]</ref><ref type="bibr" target="#b43">[34]</ref><ref type="bibr" target="#b44">[35]</ref><ref type="bibr" target="#b45">[36]</ref><ref type="bibr" target="#b46">[37]</ref><ref type="bibr" target="#b48">[38]</ref><ref type="bibr" target="#b50">[39]</ref>.</s><s>The latter idea is supported by a recent study showing that a higher level of putative CD34 + /CD38 --LSC is associated with a worse prognosis <ref type="bibr" target="#b51">[40]</ref>.</s></p><p><s>In conclusion, our novel flow cytometric AML maturity score allows for a prognostic stratification of newly diagnosed AML and gives additional prognostic information particularly in the intermediate risk group according to ELN.</s><s>Within the ELN intermediate risk group, our maturity score might be an additional tool for choosing the most appropriate (risk-adapted) post remission therapy, particularly in those patients with a high overall transplantation-associated risk.</s><s>Furthermore, the flow cytometric score may be helpful in cases, in which cytogenetic and/or molecular data for prognostic stratification are not available.</s><s>Nevertheless, before routine use, our score should be evaluated in another large AML cohort.</s><s>9</s></p><note type="other">Figure Legends</note></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Table 1 Baseline characteristics of the 300 patients included in the study</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Table 2a</head><p><s>AML maturity score.</s><s>According to quantitative antigen expression, acute myeloid leukemias were either classified as "immature" (high score) or "mature" (low score)</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Table 2b</head><p><s>Distribution of patients in the different groups of the "maturity score" Table <ref type="table">3</ref> Accumulation of cytogenetic and molecular genetic results in AML-ma and AML-im groups   • NPM1 mut 28 (10.9%)</s></p><p><s>• MLL mut 12 (4.7%)</s></p><p><s>• FLT3-TKD mut 3 (1.2%)</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>WHO classification of AML (2008)</head><p><s>• AML with recurrent genetic abnormalities 65 (21.7%)</s></p><p><s>• AML with myelodysplasia-related changes 73 (24.3%)</s></p><p><s>• Therapy-related myeloid neoplasms 5 (1.7%)</s></p><p><s>• AML, not otherwise specified 144 (48.0%)</s></p><p><s>• Acute leukemias of ambiguous lineage 13 (4.3%)</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head></head><label></label><figDesc><div><p><s>Fig 1b).</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head></head><label></label><figDesc><div><p><s>Fig 3 shows the distribution of our AML cohort within the different ELN risk groups.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Fig 1 Fig 2</head><label>12</label><figDesc><div><p><s>Fig 1 Relapse-free survival (Fig 1a) and overall survival (Fig 1b) of all patients, &lt;60</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>Fig 3 Fig 4</head><label>34</label><figDesc><div><p><s>Fig 3 Subgroups according to the ELN risk stratification: each subgroup is divided</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1 .</head><label>1</label><figDesc><div><p><s>Baseline characteristics of the 300 patients included in the study.</s></p></div></figDesc><table><row><cell>No. of patients</cell></row></table></figure>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgements</head><p><s>TS and AF contributed equally to this manuscript.</s><s>JW, AF, and TS were the principal investigators and take primary responsibility for the paper; BD, JW, AF, TB, and AP recruited the patients; JW, IA, ST, AF, and AS performed the laboratory work for this study; JW, AF, and TS participated in the statistical analysis; JW, AF, and TS coordinated the research; JW, AF, and TS wrote the paper.</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Compliance with Ethical Standards</head><p><s>Ethical approval: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.</s><s>Informed consent was obtained from all patients concerning the diagnostic procedures related to AML diagnosis and treatment.</s><s>For the retrospective analysis, formal consent is not required.</s><s>This article does not contain any studies with animals performed by any of the authors.</s></p><p><s>Conflict of interest: The authors declare that they have no conflict of interest.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Table 2a</head><p><s>. AML maturity score.</s><s>According to quantitative antigen expression, acute myeloid leukemias were either classified as "immature" (high score, 1.5-5 points ) or "mature" (low score, 0-1 points).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Antigen</head></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">SEER data submission</title>
		<author>
			<persName><forename type="first">N</forename><surname>Howlader</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Noone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Krapcho</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Garshell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Neyman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">F</forename><surname>Altekruse</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename><surname>Kosary</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Yu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Ruhl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Tatalovich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Cho</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Mariotto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Lewis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">S</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename><surname>Feuer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Cronin</surname></persName>
		</author>
		<ptr target="http://seer.cancer.gov/csr/1975_2010/" />
	</analytic>
	<monogr>
		<title level="m">SEER Cancer Statistics Review</title>
				<imprint>
			<date type="published" when="1975">1975-2010. November 2012. 2013</date>
		</imprint>
		<respStmt>
			<orgName>National Cancer Institute. Bethesda, MD</orgName>
		</respStmt>
	</monogr>
	<note>posted to the SEER web site</note>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Acute myeloid leukaemia</title>
		<author>
			<persName><forename type="first">E</forename><surname>Estey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Dohner</surname></persName>
		</author>
		<idno type="DOI">10.1016/S0140-</idno>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">368</biblScope>
			<biblScope unit="issue">9550</biblScope>
			<biblScope unit="page" from="1894" to="1907" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Cytogenetics in acute leukemia</title>
		<author>
			<persName><forename type="first">K</forename><surname>Mrozek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">A</forename><surname>Heerema</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">D</forename><surname>Bloomfield</surname></persName>
		</author>
		<idno type="DOI">10.1016/S0268-960X(03)00040-7</idno>
	</analytic>
	<monogr>
		<title level="j">Blood reviews</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="115" to="136" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">F</forename><surname>Schlenk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Dohner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Krauter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Frohling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Corbacioglu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Bullinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Habdank</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Spath</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Morgan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Benner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Schlegelberger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Heil</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ganser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Dohner</surname></persName>
		</author>
		<idno type="DOI">10.1056/NEJMoa074306</idno>
	</analytic>
	<monogr>
		<title level="j">The New England journal of medicine</title>
		<imprint>
			<biblScope unit="volume">358</biblScope>
			<biblScope unit="issue">18</biblScope>
			<biblScope unit="page" from="1909" to="1918" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">H</forename><surname>Dohner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">H</forename><surname>Estey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Amadori</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">R</forename><surname>Appelbaum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Buchner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">K</forename><surname>Burnett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Dombret</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Fenaux</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Grimwade</forename></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet</title>
		<author>
			<persName><forename type="first">D</forename><surname>Larson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Lo-Coco</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Naoe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Niederwieser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Ossenkoppele</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Sanz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Sierra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Tallman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Lowenberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Bloomfield</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">D</forename></persName>
		</author>
		<idno type="DOI">10.1182/blood-2009-07-235358</idno>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">115</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="453" to="474" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children&apos;s Leukaemia Working Parties</title>
		<author>
			<persName><forename type="first">D</forename><surname>Grimwade</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Walker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Oliver</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Wheatley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Harrison</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Harrison</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Rees</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Hann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Stevens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Burnett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Goldstone</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">92</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="2322" to="2333" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Byrd</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Mrozek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">K</forename><surname>Dodge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Carroll</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">G</forename><surname>Edwards</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Arthur</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Pettenati</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Patil</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">W</forename><surname>Rao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Watson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">R</forename><surname>Koduru</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">O</forename><surname>Moore</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Stone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Mayer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename><surname>Feldman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">R</forename><surname>Davey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Schiffer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Larson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">D</forename><surname>Bloomfield</surname></persName>
		</author>
		<idno type="DOI">10.1182/blood-2002-03-0772</idno>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">100</biblScope>
			<biblScope unit="issue">13</biblScope>
			<biblScope unit="page" from="4325" to="4336" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">The clinical significance of cytogenetic abnormalities in acute myeloid leukaemia</title>
		<author>
			<persName><forename type="first">D</forename><surname>Grimwade</surname></persName>
		</author>
		<idno type="DOI">10.1053/beha.2001.0152</idno>
	</analytic>
	<monogr>
		<title level="j">Best practice &amp; research Clinical haematology</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="497" to="529" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Molecular characterization of acute myeloid leukemia</title>
		<author>
			<persName><forename type="first">K</forename><surname>Dohner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Dohner</surname></persName>
		</author>
		<idno type="DOI">10.3324/haematol.1334511</idno>
	</analytic>
	<monogr>
		<title level="j">Haematologica</title>
		<imprint>
			<biblScope unit="volume">93</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="976" to="982" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Influence of new molecular prognostic markers in patients with karyotypically normal acute myeloid leukemia: recent advances</title>
		<author>
			<persName><forename type="first">K</forename><surname>Mrozek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Dohner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">D</forename><surname>Bloomfield</surname></persName>
		</author>
		<idno type="DOI">10.1097/MOH.0b013e32801684c7</idno>
	</analytic>
	<monogr>
		<title level="j">Current opinion in hematology</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="106" to="114" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">CD34 expression fails to predict the outcome in adult acute myeloid leukemia</title>
		<author>
			<persName><forename type="first">S</forename><surname>Ciolli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Leoni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Caporale</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Pascarella</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Salti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Rossi-Ferrini</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Haematologica</title>
		<imprint>
			<biblScope unit="volume">78</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="151" to="155" />
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Prognostic relevance of immunophenotyping in 379 patients with acute myeloid leukemia</title>
		<author>
			<persName><forename type="first">H</forename><surname>Chang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Salma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><forename type="middle">L</forename><surname>Yi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Patterson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Brien</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Minden</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leukemia research</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="43" to="48" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">C</forename><surname>Plesa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Chelghoum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Plesa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Elhamri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Tigaud</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Michallet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Dumontet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Thomas</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Prognostic value of immunophenotyping in elderly patients with acute myeloid leukemia: a single-institution experience</title>
		<idno type="DOI">10.1002/cncr.23219</idno>
	</analytic>
	<monogr>
		<title level="j">Cancer</title>
		<imprint>
			<biblScope unit="volume">112</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="572" to="580" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<monogr>
		<title level="m" type="main">The prognostic significance of the CD34 antigen in acute myeloid leukaemia</title>
		<author>
			<persName><forename type="first">H</forename><surname>Myint</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">P</forename><surname>Lucie</surname></persName>
		</author>
		<imprint>
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title/>
		<idno type="DOI">10.3109/10428199209049798</idno>
	</analytic>
	<monogr>
		<title level="j">Leukemia &amp; lymphoma</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="issue">5-6</biblScope>
			<biblScope unit="page" from="425" to="429" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<monogr>
		<title level="m" type="main">Diagnostic Techniques in Hematological Malignancies. Cambride</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">N</forename><surname>Erber</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2010">2010</date>
			<publisher>Cambridge University Press</publisher>
			<biblScope unit="page" from="31" to="33" />
			<pubPlace>United Kingdom</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">G</forename><surname>Juliusson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Antunovic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Derolf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Lehmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Mollgard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Stockelberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Tidefelt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Wahlin</surname></persName>
		</author>
		<author>
			<persName><surname>Hoglund</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry</title>
		<author>
			<persName><forename type="first">M</forename></persName>
		</author>
		<idno type="DOI">10.1182/blood-2008-07-172007</idno>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">113</biblScope>
			<biblScope unit="issue">18</biblScope>
			<biblScope unit="page" from="4179" to="4187" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Prognostic relevance of the expression of Tdt and CD7 in 335 cases of acute myeloid leukemia</title>
		<author>
			<persName><forename type="first">A</forename><surname>Venditti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Del</forename><surname>Poeta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Buccisano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Tamburini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Cox-Froncillo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Aronica</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Bruno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Del</forename><surname>Moro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Epiceno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Battaglia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Forte</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Postorino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Cordero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Santinelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Amadori</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="1056" to="1063" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Acute myeloid leukaemia M0: haematological, immunophenotypic and cytogenetic characteristics and their prognostic significance: an analysis in 241 patients</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Bene</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bernier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">O</forename><surname>Casasnovas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Castoldi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Doekharan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Van Der Holt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Knapp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Lemez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">D</forename><surname>Ludwig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Matutes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Orfao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Schoch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Sperling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">B</forename><surname>Van't Veer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">British journal of haematology</title>
		<imprint>
			<biblScope unit="volume">113</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="737" to="745" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Minimally differentiated acute myeloid leukemia (AML-M0): comparison of 25 cases with other French-American-British subtypes</title>
		<author>
			<persName><forename type="first">A</forename><surname>Venditti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Del</forename><surname>Poeta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Buccisano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Tamburini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Cox</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Stasi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Bruno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Aronica</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Maffei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Suppo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Simone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Forte</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Cordero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Postorino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Tufilli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Isacchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Masi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Papa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Amadori</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">89</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="621" to="629" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">A</forename><surname>Cuneo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ferrant</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Michaux</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Boogaerts</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Demuynck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Van Orshoven</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Criel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Stul</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Dal</forename><surname>Cin</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Cytogenetic profile of minimally differentiated (FAB M0) acute myeloid leukemia: correlation with clinicobiologic findings</title>
		<author>
			<persName><forename type="first">J</forename><surname>Hernandez</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">85</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="3688" to="3694" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Significance of FAB subclassification of &quot;acute myeloid leukemia, NOS&quot; in the 2008 WHO classification: analysis of 5848 newly diagnosed patients</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Walter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Othus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">K</forename><surname>Burnett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Lowenberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Kantarjian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Ossenkoppele</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">K</forename><surname>Hills</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">G</forename><surname>Van Montfort</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Ravandi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Evans</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Pierce</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">R</forename><surname>Appelbaum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">H</forename><surname>Estey</surname></persName>
		</author>
		<idno type="DOI">10.1182/blood-2012-10-462440</idno>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">121</biblScope>
			<biblScope unit="issue">13</biblScope>
			<biblScope unit="page" from="2424" to="2431" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">H</forename><surname>Zhu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">R</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Jiang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Lu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">Z</forename><surname>Qin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Jiang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Bao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">R</forename><surname>Ruan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Jiang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Huang</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2013">2013</date>
			<biblScope unit="page">D34</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">expression on bone marrow blasts is a novel predictor of poor prognosis independent of FlT3-ITD in acute myeloid leukemia with the NPM1-mutation</title>
		<idno type="DOI">10.1016/j.leukres.2013.02.007</idno>
	</analytic>
	<monogr>
		<title level="j">Leukemia research</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="624" to="630" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">CD34 expression predicts an adverse outcome in patients with NPM1-positive acute myeloid leukemia</title>
		<author>
			<persName><forename type="first">H</forename><surname>Dang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kamel-Reid</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Brandwein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Chang</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.humpath.2013.03.007</idno>
	</analytic>
	<monogr>
		<title level="j">Human pathology</title>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="2038" to="2046" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">M</forename><surname>Breccia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Propris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Stefanizzi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Raponi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Molica</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Colafigli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Minotti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Latagliata</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Diverio</forename></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Negative prognostic value of CD34 antigen also if expressed on a small population of acute promyelocytic leukemia cells</title>
		<author>
			<persName><forename type="first">D</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Guarini</forename><forename type="middle">A</forename><surname>Foa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename></persName>
		</author>
		<idno type="DOI">10.1007/s00277-014-2130-0</idno>
	</analytic>
	<monogr>
		<title level="j">Annals of hematology</title>
		<imprint>
			<biblScope unit="volume">93</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="1819" to="1823" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">The origin and evolution of mutations in acute myeloid leukemia</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Welch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Ley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Link</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Miller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Larson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Koboldt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">D</forename><surname>Wartman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">L</forename><surname>Lamprecht</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Xia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Kandoth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Fulton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Mclellan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Dooling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Wallis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Harris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">K</forename><surname>Schmidt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Kalicki-Veizer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Lu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>O'laughlin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Mcmichael</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">D</forename><surname>Delehaunty</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Fulton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">J</forename><surname>Magrini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Mcgrath</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">T</forename><surname>Demeter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">L</forename><surname>Vickery</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Hundal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">L</forename><surname>Cook</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">W</forename><surname>Swift</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Reed</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Alldredge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">N</forename><surname>Wylie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Walker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Watson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Heath</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">D</forename><surname>Shannon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Varghese</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Nagarajan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Payton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Baty</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kulkarni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Klco</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Tomasson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Westervelt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Walter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">A</forename><surname>Graubert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Dipersio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Ding</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">R</forename><surname>Mardis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">K</forename><surname>Wilson</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.cell.2012.06.023</idno>
	</analytic>
	<monogr>
		<title level="j">Cell</title>
		<imprint>
			<biblScope unit="volume">150</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="264" to="278" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Genomic heterogeneity in acute leukemia</title>
		<author>
			<persName><forename type="first">K</forename><surname>Paulsson</surname></persName>
		</author>
		<idno type="DOI">10.1159/000346797</idno>
	</analytic>
	<monogr>
		<title level="j">Cytogenetic and genome research</title>
		<imprint>
			<biblScope unit="volume">139</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="174" to="180" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">L</forename><surname>Ding</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Ley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Larson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Miller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Koboldt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Welch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">K</forename><surname>Ritchey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Young</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Lamprecht</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Mclellan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Mcmichael</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Wallis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Lu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Shen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Harris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Dooling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Fulton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">L</forename><surname>Fulton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Chen</forename></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">K</forename><surname>Schmidt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Kalicki-Veizer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Magrini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">J</forename><surname>Cook</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Mcgrath</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Vickery</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">L</forename><surname>Wendl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Heath</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Watson</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<monogr>
		<title/>
		<author>
			<persName><surname>Ma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Link</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Tomasson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">D</forename><surname>Shannon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Payton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kulkarni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Westervelt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Walter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">A</forename><surname>Graubert</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">R</forename><surname>Mardis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">K</forename><surname>Wilson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Dipersio</surname></persName>
		</author>
		<idno type="DOI">10.1038/nature1073813</idno>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">481</biblScope>
			<biblScope unit="issue">7382</biblScope>
			<biblScope unit="page" from="506" to="510" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival</title>
		<author>
			<persName><forename type="first">A</forename><surname>Van Rhenen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Feller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kelder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">H</forename><surname>Westra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Rombouts</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Zweegman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Van Der Pol</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Waisfisz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Ossenkoppele</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Schuurhuis</surname></persName>
		</author>
		<idno type="DOI">10.1158/1078-0432.CCR-05-0468</idno>
	</analytic>
	<monogr>
		<title level="j">Clinical cancer research : an official journal of the American Association for Cancer Research</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="issue">18</biblScope>
			<biblScope unit="page" from="6520" to="6527" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Detection, isolation, and stimulation of quiescent primitive leukemic progenitor cells from patients with acute myeloid leukemia (AML)</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Guan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Gerhard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Hogge</surname></persName>
		</author>
		<idno type="DOI">10.1182/blood-2002-10-3062</idno>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">101</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="3142" to="3149" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Gentles</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">K</forename><surname>Plevritis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Majeti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Alizadeh</surname></persName>
		</author>
		<idno type="DOI">10.1001/jama.2010.1862</idno>
	</analytic>
	<monogr>
		<title level="j">JAMA : the journal of the American Medical Association</title>
		<imprint>
			<biblScope unit="volume">304</biblScope>
			<biblScope unit="issue">24</biblScope>
			<biblScope unit="page" from="2706" to="2715" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Analysis of treatment failure in patients with minimally differentiated acute myeloid leukemia (AML-M0)</title>
		<author>
			<persName><forename type="first">R</forename><surname>Stasi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Del</forename><surname>Poeta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Venditti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Masi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Stipa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Dentamaro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Cox</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Dallapiccola</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Papa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">83</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="1619" to="1625" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Minimally differentiated acute myeloid leukaemia (AML-M0): cytochemical, immunophenotypic and cytogenetic analysis of 19 cases</title>
		<author>
			<persName><forename type="first">A</forename><surname>Venditti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Del</forename><surname>Poeta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Stasi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Masi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bruno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Buccisano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Cox</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Coppetelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Aronica</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Simone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">British journal of haematology</title>
		<imprint>
			<biblScope unit="volume">88</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="784" to="793" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">V</forename><surname>Krivtsov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Twomey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Feng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Stubbs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Faber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Levine</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">C</forename><surname>Hahn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>Gilliland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">R</forename><surname>Golub</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Armstrong</surname></persName>
		</author>
		<idno type="DOI">10.1038/nature04980</idno>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">442</biblScope>
			<biblScope unit="issue">7104</biblScope>
			<biblScope unit="page" from="818" to="822" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors</title>
		<author>
			<persName><forename type="first">A</forename><surname>Cozzio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Passegue</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">M</forename><surname>Ayton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Karsunky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Cleary</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">L</forename><surname>Weissman</surname></persName>
		</author>
		<idno type="DOI">10.1101/gad.1143403</idno>
	</analytic>
	<monogr>
		<title level="j">Genes &amp; development</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="issue">24</biblScope>
			<biblScope unit="page" from="3029" to="3035" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">J</forename><surname>Huntly</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Shigematsu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Deguchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">H</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Mizuno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Duclos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Rowan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Amaral</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Curley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">R</forename><surname>Williams</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Akashi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>Gilliland</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ccr.2004.10.015</idno>
	</analytic>
	<monogr>
		<title level="j">Cancer cell</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="587" to="596" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell</title>
		<author>
			<persName><forename type="first">D</forename><surname>Bonnet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Dick</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature medicine</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="730" to="737" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">T</forename><surname>Lapidot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Sirard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Vormoor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Murdoch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Hoang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Caceres-Cortes</surname></persName>
		</author>
		<imprint>
			<pubPlace>Minden M, Paterson B, Caligiuri</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">A cell initiating human acute myeloid leukaemia after transplantation into SCID mice</title>
		<author>
			<persName><forename type="first">Dick</forename><surname>Ma</surname></persName>
		</author>
		<author>
			<persName><surname>Je</surname></persName>
		</author>
		<idno type="DOI">10.1038/367645a0</idno>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">367</biblScope>
			<biblScope unit="issue">6464</biblScope>
			<biblScope unit="page" from="645" to="648" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">V</forename><surname>Krivtsov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Figueroa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">U</forename><surname>Sinha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Stubbs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Feng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Valk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Delwel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Dohner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Bullinger</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">Cell of origin determines clinically relevant subtypes of MLLrearranged AML</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Kung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Melnick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Armstrong</surname></persName>
		</author>
		<idno type="DOI">10.1038/leu.2012.363</idno>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="852" to="860" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">Identification of leukemia stem cells in acute myeloid leukemia and their clinical relevance</title>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">T</forename><surname>Hoang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Zepeda-Moreno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Ho</surname></persName>
		</author>
		<idno type="DOI">10.1002/biot.201100350</idno>
	</analytic>
	<monogr>
		<title level="j">Biotechnology journal</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="779" to="788" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">Leukemic stem cell frequency: a strong biomarker for clinical outcome in acute myeloid leukemia</title>
		<author>
			<persName><forename type="first">M</forename><surname>Terwijn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Zeijlemaker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kelder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">P</forename><surname>Rutten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">N</forename><surname>Snel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Scholten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Pabst</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Verhoef</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Lowenberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Zweegman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Ossenkoppele</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Schuurhuis</surname></persName>
		</author>
		<idno type="DOI">10.1371/journal.pone.0107587</idno>
	</analytic>
	<monogr>
		<title level="j">PloS one</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page">e107587</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
